Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma
Liver Cancer · 02.04.2026 · 1-13
DOI: 10.1159/000550924 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 02.04.2026. Verfasst von Atsushi Hiraoka und 58 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Atezolizumab plus bevacizumab (Atez/Bev) was the first immune checkpoint inhibitor regimen approved in 2020 for unresectable hepatocellular carcinoma (uHCC), followed by durvalumab plus tremelimumab (Dur/Tre) in 2023. There is very little data available comparing the efficacy and safety of Atez/Bev with those of Dur/Tre. This study aimed to clarify the therapeutic outcomes and safety of Atez/Bev and Dur/Tre.
Methods
We retrospectively analyzed patients with uHCC (BCLC-B/C and Child-Pugh class A) treated with Atez/Bev (n = 302) or Dur/Tre (n = 129) as first-line systemic therapy across multiple institutions between 2023 and 2025. A retrospective comparison of the treatment outcomes and safety of Atez/Bev and Dur/Tre was conducted.
Results
The objective response rate and disease control rate were comparable between the Atez/Bev and Dur/Tre groups (31.8%/71.9% vs. 28.7%/63.6%, p = 0.570/p = 0.110, respectively). Median progression-free survival (PFS) was longer with Atez/Bev (9.1 vs. 5.0 months, p = 0.002), while OS was comparable (25.6 vs. 22.1 months, p = 0.172). Similar results were shown after adjusting with inverse probability weighting (IPW). Grade 5 immune-related adverse events occurred in 0.3% (n = 1, interstitial pneumonia) of the patients receiving Atez/Bev and 0.8% (n = 1, colitis) of those receiving Dur/Tre. In the Cox hazard analysis adjusted with IPW, Dur/Tre demonstrated a favorable trend in OS (hazard ratio [HR]
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
- Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
- Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
- Department of Gastroenterology and Neurology, Kagawa University, Takamatsu, Japan.
Zitieren
APA
Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Nishimura, T., Tsuji, K., Ishikawa, T., Tajiri, K., Tanaka, H., Toyoda, H., Ogawa, C., Hatanaka, T., Kakizaki, S., Kawata, K., Naganuma, A., …, & HCC 48 Group (2026). Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma. Liver Cancer, 1-13. https://doi.org/10.1159/000550924
Vancouver
Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, et al. Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma. Liver Cancer. 2026:1-13. doi:10.1159/000550924
BibTeX
@article{Hiraoka2026,
author = {Hiraoka, Atsushi and Tada, Toshifumi and Hirooka, Masashi and Kariyama, Kazuya and Tani, Joji and Atsukawa, Masanori and Takaguchi, Koichi and Itobayashi, Ei and Nishimura, Takashi and Tsuji, Kunihiko and Ishikawa, Toru and Tajiri, Kazuto and Tanaka, Hironori and Toyoda, Hidenori and Ogawa, Chikara and Hatanaka, Takeshi and Kakizaki, Satoru and Kawata, Kazuhito and Naganuma, Atsushi and Kosaka, Hisashi and Matono, Tomomitsu and Kuroda, Hidekatsu and Yata, Yutaka and Nishikawa, Hiroki and Imai, Michitaka and Aoki, Tomoko and Ochi, Hironori and Tamai, Hideyuki and Komatsu, Shohei and Matsuura, Takanori and Ueda, Yoshihide and Kim, Soo Ki and Ohama, Hideko and Tada, Fujimasa and Nakamura, Shinichiro and Nakamura, Yoshiko and Yoshida, Osamu and Nouso, Kazuhiro and Morishita, Asahiro and Itokawa, Norio and Okubo, Tomomi and Arai, Taeang and Tsutsui, Akemi and Nagano, Takuya and Fukunishi, Shinya and Tanaka, Kazunari and Koshiyama, Yuichi and Kanayama, Yuki and Noritake, Hidenao and Enomoto, Hirayuki and Matsui, Kosuke and Kaibori, Masaki and Okamura, Jumpei and Fukumoto, Takumi and Hiasa, Yoichi and Kudo, Masatoshi and Kumada, Takashi and RELPEC Group, RELPEC Group and HCC 48 Group, HCC 48 Group},
title = {Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma},
journal = {Liver Cancer},
year = {2026},
pages = {1--13},
doi = {10.1159/000550924}
}
EUVIMED